On the other hand, previous studies have reported that this chemical marker exhibits strong inhibition of the formation of advanced glycation end-product (AGE) and butyrylcholinesterase (BChE) for the treatment of Alzheimer’s disease, and showed a protective effect on LPS-induced renal inflammation in mice, and exhibited moderate anti-proliferation effect on PC3 human androgen-independent prostate cancer cells (Park and Whang, 2020; Li et al., 2010; Liu et al., 2006; Ye et al., 2015). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.